INO vs. STIM, SMTI, ZIMV, RCEL, SNWV, NVRO, NYXH, ELMD, PDEX, and DRTS
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Neuronetics (STIM), Sanara MedTech (SMTI), ZimVie (ZIMV), AVITA Medical (RCEL), SANUWAVE Health (SNWV), Nevro (NVRO), Nyxoah (NYXH), Electromed (ELMD), Pro-Dex (PDEX), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
Inovio Pharmaceuticals vs.
Inovio Pharmaceuticals (NASDAQ:INO) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Neuronetics has higher revenue and earnings than Inovio Pharmaceuticals. Neuronetics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 3 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.62 beat Neuronetics' score of 0.47 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.
Inovio Pharmaceuticals has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.
Inovio Pharmaceuticals received 591 more outperform votes than Neuronetics when rated by MarketBeat users. Likewise, 70.87% of users gave Inovio Pharmaceuticals an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.
Inovio Pharmaceuticals presently has a consensus target price of $12.20, suggesting a potential upside of 550.67%. Neuronetics has a consensus target price of $5.50, suggesting a potential upside of 25.43%. Given Inovio Pharmaceuticals' higher probable upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Neuronetics.
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 9.8% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Inovio Pharmaceuticals has a net margin of 0.00% compared to Neuronetics' net margin of -50.09%. Inovio Pharmaceuticals' return on equity of -118.17% beat Neuronetics' return on equity.
Summary
Inovio Pharmaceuticals beats Neuronetics on 9 of the 17 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INO) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy INO Stock Free INO Stock Alerts